ESOPHAGEAL SQUAMOUS CELL CARCINOMA

This study tests whether adding the drug durvalumab to standard chemoradiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 640 adults will receive either durvalumab or a placebo alongside their radiation and chemotherapy. The goal is to s…

This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can help people with esophageal cancer. The goal is to see if this combination can shrink tumors more effectively and lower the chance of cancer coming back after surgery. About 48 adults…

This study tests whether adding the experimental drug LBL-007 to standard immunotherapy (tislelizumab) and chemotherapy helps shrink tumors or delay cancer growth in people with advanced esophageal cancer that cannot be removed by surgery. About 118 adults with this type of cance…

This study tests whether adding two targeted drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery can help shrink tumors in people with a certain type of esophageal cancer. About 48 adults with locally advanced but removable cancer will take part. The main…

This study tests whether adding immunotherapy (a PD-1 checkpoint inhibitor) to a medium-dose three-drug chemotherapy regimen, along with probiotics and an immune booster, can improve outcomes for people with advanced esophageal cancer. About 50 participants will receive the treat…

This study tests whether adding tiragolumab to atezolizumab can help prevent esophageal cancer from returning after standard chemoradiation. About 760 people with inoperable esophageal squamous cell carcinoma will receive either the drug combination, atezolizumab alone, or placeb…

This study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…

This study tests a new drug called MCLA-129 in people with advanced lung, stomach, esophageal, head/neck, or colorectal cancers that have not responded to standard treatments. The drug is a bispecific antibody designed to attack two cancer-related targets at once. The goal is to …

This early-phase study tests whether giving two drugs—camrelizumab and palbociclib—before surgery is safe and feasible for people with a type of esophageal cancer that can be removed. The trial involves 6 participants and focuses on side effects and whether the treatment delays s…

This phase 3 study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has worsened after initial treatment. About 497 participants will be randomly assigned to receive either BL-B01D1 or a doctor-chosen chemo. The goal i…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …

This trial was designed to test a new drug (S095033) combined with chemotherapy (paclitaxel) in people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to see if the combination was safe and could shrink tumors. However, the study was withdrawn before …

This study looks at adding immunotherapy (tislelizumab) to chemotherapy for people with a high-risk type of esophageal cancer that didn't fully respond to initial treatment. The goal is to see if this combination can improve outcomes and help patients live longer. About 80 partic…

This study tests whether adding the drug apatinib to standard chemotherapy and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will receive either the standard treatment or the standard treatment plus apatinib. T…

This study tested whether adding two immunotherapy drugs, nivolumab and cetuximab, to standard chemoradiation could improve outcomes for people with a certain type of advanced esophageal cancer. Twelve participants who had not received prior treatment received the drug combinatio…

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…